These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 19724783)

  • 1. Immunotherapy for cancer: synthetic carbohydrate-based vaccines.
    Buskas T; Thompson P; Boons GJ
    Chem Commun (Camb); 2009 Sep; (36):5335-49. PubMed ID: 19724783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent development in carbohydrate-based cancer vaccines.
    Guo Z; Wang Q
    Curr Opin Chem Biol; 2009 Dec; 13(5-6):608-17. PubMed ID: 19766052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A vision for vaccines built from fully synthetic tumor-associated antigens: from the laboratory to the clinic.
    Wilson RM; Danishefsky SJ
    J Am Chem Soc; 2013 Oct; 135(39):14462-72. PubMed ID: 23944352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthetic carbohydrate-based anticancer vaccines: the Memorial Sloan-Kettering experience.
    Zhu J; Warren JD; Danishefsky SJ
    Expert Rev Vaccines; 2009 Oct; 8(10):1399-413. PubMed ID: 19803761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthetic glycopeptides for the development of cancer vaccines.
    Liakatos A; Kunz H
    Curr Opin Mol Ther; 2007 Feb; 9(1):35-44. PubMed ID: 17330400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Towards a fully synthetic MUC1-based anticancer vaccine: efficient conjugation of glycopeptides with mono-, di-, and tetravalent lipopeptides using click chemistry.
    Cai H; Huang ZH; Shi L; Zhao YF; Kunz H; Li YM
    Chemistry; 2011 May; 17(23):6396-406. PubMed ID: 21538615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fully synthetic self-adjuvanting thioether-conjugated glycopeptide-lipopeptide antitumor vaccines for the induction of complement-dependent cytotoxicity against tumor cells.
    Cai H; Sun ZY; Huang ZH; Shi L; Zhao YF; Kunz H; Li YM
    Chemistry; 2013 Feb; 19(6):1962-70. PubMed ID: 23280874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospects for total synthesis: a vision for a totally synthetic vaccine targeting epithelial tumors.
    Keding SJ; Danishefsky SJ
    Proc Natl Acad Sci U S A; 2004 Aug; 101(33):11937-42. PubMed ID: 15280546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Recent advance in carbohydrate-based cancer vaccines].
    Huo CX; Ye XS
    Yao Xue Xue Bao; 2012 Mar; 47(3):261-70. PubMed ID: 22645748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis of selected LeY and KH-1 analogues: a medicinal chemistry approach to vaccine optimization.
    Spassova MK; Bornmann WG; Ragupathi G; Sukenick G; Livingston PO; Danishefsky SJ
    J Org Chem; 2005 Apr; 70(9):3383-95. PubMed ID: 15844973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterovalent Glycodendrimers as Epitope Carriers for Antitumor Synthetic Vaccines.
    Pifferi C; Thomas B; Goyard D; Berthet N; Renaudet O
    Chemistry; 2017 Nov; 23(64):16283-16296. PubMed ID: 28845889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of the immunogenicity of synthetic carbohydrate vaccines by chemical modifications of STn antigen.
    Yang F; Zheng XJ; Huo CX; Wang Y; Zhang Y; Ye XS
    ACS Chem Biol; 2011 Mar; 6(3):252-9. PubMed ID: 21121644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carbohydrate-based cancer vaccines: target cancer with sugar bullets.
    Liu CC; Ye XS
    Glycoconj J; 2012 Aug; 29(5-6):259-71. PubMed ID: 22669462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic carbohydrate-based antitumor vaccines: challenges and opportunities.
    Ouerfelli O; Warren JD; Wilson RM; Danishefsky SJ
    Expert Rev Vaccines; 2005 Oct; 4(5):677-85. PubMed ID: 16221069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increasing the antigenicity of synthetic tumor-associated carbohydrate antigens by targeting Toll-like receptors.
    Ingale S; Wolfert MA; Buskas T; Boons GJ
    Chembiochem; 2009 Feb; 10(3):455-63. PubMed ID: 19145607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A fully synthetic vaccine consisting of a tumor-associated glycopeptide antigen and a T-cell epitope for the induction of a highly specific humoral immune response.
    Dziadek S; Hobel A; Schmitt E; Kunz H
    Angew Chem Int Ed Engl; 2005 Nov; 44(46):7630-5. PubMed ID: 16247815
    [No Abstract]   [Full Text] [Related]  

  • 17. Synthetic antitumor vaccines from tetanus toxoid conjugates of MUC1 glycopeptides with the Thomsen-Friedenreich antigen and a fluorine-substituted analogue.
    Hoffmann-Röder A; Kaiser A; Wagner S; Gaidzik N; Kowalczyk D; Westerlind U; Gerlitzki B; Schmitt E; Kunz H
    Angew Chem Int Ed Engl; 2010 Nov; 49(45):8498-503. PubMed ID: 20878823
    [No Abstract]   [Full Text] [Related]  

  • 18. Synthesis and vaccine evaluation of the tumor-associated carbohydrate antigen RM2 from prostate cancer.
    Chuang HY; Ren CT; Chao CA; Wu CY; Shivatare SS; Cheng TJ; Wu CY; Wong CH
    J Am Chem Soc; 2013 Jul; 135(30):11140-50. PubMed ID: 23819648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carbohydrate vaccines as immunotherapy for cancer.
    Slovin SF; Keding SJ; Ragupathi G
    Immunol Cell Biol; 2005 Aug; 83(4):418-28. PubMed ID: 16033538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. From synthesis to biologics: preclinical data on a chemistry derived anticancer vaccine.
    Zhu J; Wan Q; Lee D; Yang G; Spassova MK; Ouerfelli O; Ragupathi G; Damani P; Livingston PO; Danishefsky SJ
    J Am Chem Soc; 2009 Jul; 131(26):9298-303. PubMed ID: 19518111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.